FDA Imposes Full Clinical Hold on Lead Drug ARD-101, Halting Phase 3 Trials
AARD sits 82% above its 52-week low of $3.35.
Summary
Aardvark Therapeutics announced that the FDA has placed a full clinical hold on its lead investigational drug, ARD-101, halting all ongoing clinical studies, including Phase 3 trials for Prader-Willi Syndrome.
Key Events · Product Development and Regulatory · AARD
-
FDA Imposes Full Clinical Hold
The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on Aardvark Therapeutics' investigational new drug application (IND) for ARD-101.
-
Phase 3 Trials Halted
The clinical hold applies to all ongoing studies under the IND, including the Phase 3 HERO trial and the open-label extension (OLE) trial for Prader-Willi Syndrome.
-
Follows Voluntary Pause
This regulatory action follows the company's previously announced voluntary pause in its Phase 3 trials due to safety observations.
-
Company to Unblind Data
Aardvark Therapeutics plans to unblind clinical data from both trials to assess efficacy and safety, informing next steps for the ARD-101 program.
Analysis · AARD · Life Sciences
The FDA's decision to place a full clinical hold on ARD-101 is a critical setback for Aardvark Therapeutics, as it directly impacts their lead drug candidate in Phase 3 trials for Prader-Willi Syndrome. This escalates the previously announced voluntary trial pauses to a regulatory mandate, casting significant doubt on the program's future and the company's primary value driver. While the company plans to unblind data and engage with the FDA, the hold represents a major blow to investor confidence and the company's ability to bring ARD-101 to market.
At the time of this filing, AARD was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.8M. The 52-week trading range was $3.35 to $17.94. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.